|
Tumor Progression
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We observed that mice with both Lzts2 and Pten deletion have an earlier onset of prostate carcinomas as well as an accelerated tumor progression compared to mice with Pten or Lzts2 deletion alone.
|
28323888 |
2017 |
|
Carcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We observed that mice with both Lzts2 and Pten deletion have an earlier onset of prostate carcinomas as well as an accelerated tumor progression compared to mice with Pten or Lzts2 deletion alone.
|
28323888 |
2017 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We found that low levels of LZTS2 in NSCLC were correlated with tumor and nodal status.
|
23761130 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that low levels of LZTS2 in NSCLC were correlated with tumor and nodal status.
|
23761130 |
2013 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Using an Lzts2 knock-out mouse model, we characterized the biological role of Lzts2 in tumorigenesis.
|
23275340 |
2013 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment of Lzts2-deficient mice with a carcinogen, N-butyl-N-(4-hydroxybutyl) nitrosamine, increases the susceptibility to N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder carcinoma development.
|
23275340 |
2013 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.
|
11709705 |
2001 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.
|
11709705 |
2001 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.
|
17351128 |
2007 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.
|
17351128 |
2007 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results provide novel mechanistic insight into the biological roles of LZTS2 in lung cancer cells.
|
23761130 |
2013 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results provide novel mechanistic insight into the biological roles of LZTS2 in lung cancer cells.
|
23761130 |
2013 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results provide novel mechanistic insight into the biological roles of LZTS2 in lung cancer cells.
|
23761130 |
2013 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
These data provide the first line of evidence demonstrating that deletion of Lzts2 increases susceptibility to spontaneous and carcinogen-induced tumor development.
|
23275340 |
2013 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrate the significance of simultaneous Pten and Lzts2 deletion in oncogenic transformation in prostate cells and implicates a new mechanism for the dysregulation of Wnt/β-catenin signaling in prostate tumorigenesis.
|
28323888 |
2017 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
The qMSP analyses revealed that LZTS2 promoter methylation levels in the LSCC tumor samples were significantly higher than those in paired adjacent healthy tissue samples.
|
29499699 |
2018 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The leucine zipper tumor suppressor 2 (LZTS2) was identified as a tumor susceptibility gene within the 10q24.3 chromosomal region, and is approximately 15Mb from the PTEN locus.
|
28323888 |
2017 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
The LZTS2 gene is located at 10q24.3, which is frequently lost in a variety of human tumors.
|
17000760 |
2006 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results not only provide understanding of the molecular mechanisms by which PI3K/AKT signaling is activated but also suggest that targeting the LZTS2/PI3K/AKT signaling axis is a promising therapeutic strategy for radiosensitization of nasopharyngeal carcinoma.
|
29409973 |
2018 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
No studies to date have described methylation of the LZTS2 promoter in human cancers, including LSCC (laryngeal squamous cell carcinoma).
|
29499699 |
2018 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
|
17351128 |
2007 |
|
Deformity
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
|
17351128 |
2007 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In conclusion, our results demonstrate the critical role of miR-300 in GSLCs and its functions in LZTS2 inhibition and describe a new approach for the molecular regulation of tumor stem cells.
|
24464870 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, LZTS2 methylation levels were elevated in smokers, advanced T classified, and clinically staged patients, as well as in patients with lymph node metastases.
|
29499699 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Functionally, we showed that LZTS2 suppresses tumorigenesis and radioresistance in nasopharyngeal carcinoma in a p85-dependent manner.
|
29409973 |
2018 |